Chad is a land-locked country whose southern regions lie within the meningitis belt. Major epidemics of serogroup A meningococcal disease occurred in 1988 and 1996. More than 1,000 cases were reported each year between 2005 and 2008.. In 2009 there were 1505 meningitis cases in Chad reported to WHO, this increased to 3228 in 2010 and 5960 in 2011. The majority of the cases that were tested were group A meningococci, but some group W were also detected. MenAfriVac immunisation campaigns began in Chad in late 2011 and completed by the end of 2012. MenAfriVac was used in reactive vaccination campaigns for the first time in 2012 in Chad.
MenAfriCar’s collaborating centre in Chad is the Centre de Support en Santé Internationale (CSSI).